Variations in the Hemostatic System Induced by a Standardized Walking Test
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · May 13, 2024
Trial Information
Current as of February 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Induced venous thromboembolism is a situation in which venous thromboembolic disease is triggered by an acute event that activates hemostasis: surgery, trauma, infectious or inflammatory outbreak, etc., a situation in which the risk of spontaneous recurrence, in the absence of a new provoking circumstance, is low, leading to the suggestion, not of long-term thromboprophylaxis, but simply the transient prevention of an event when there is a new clinical event likely to activate hemostasis. One such event is acute physical exertion.
Indeed, cohort studies seem to show that regular physical a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Inclusion criteria common to both groups :
- • Patients who have given written informed consent.
- • Patients who are affiliated to or beneficiaries of a social security scheme.
- Inclusion criteria specific to the Patient Group:
- • Patients with a personal history of provoked venous thromboembolism, venous thrombosis and/or pulmonary embolism, with the last attack dating back to more than 6 months, and whose clinical phenotype did not justify long-term antithrombotic drug prophylaxis.
- Definition of provoked venous thromboembolism : The clinical criteria used to classify venous thromboembolism as provoked are :
- • First year of combined oestrogen-progestogen oral contraception, or contraception using an oestrogen-impregnated vaginal ring or transcutaneous synthetic oestrogen patch.
- • Hormonal stimulation for oocyte retrieval
- • Pregnancy and 6 weeks post-partum
- • Surgery
- • Trauma
- • Immobilisation in plaster or splint
- • Outbreak of acute infectious disease
- • Acute flare-up of inflammatory disease
- • Prolonged air travel lasting at least 4 hours
- • Prolonged strict bed rest lasting at least 3 consecutive days.
- Inclusion criteria specific to the Control Group:
- • Subjects with no personal history of venous thromboembolism
- • Subjects with no family history of venous thromboembolism in first-degree relatives
- • Subjects of the same sex and age with a tolerance of +/- 5 years in relation to the matched case.
- Exclusion Criteria:
- • Patients who are physically unable to perform the 60-minute walking test, for any reason, in particular cardiovascular contraindications to exercise (recent acute coronary syndrome unstable angina, rhythm disorders, tight aortic stenosis, cardiac heart failure, acute myocarditis, pericarditis or endocarditis endocarditis, poorly controlled hypertension, pre-stress blood pressure \> 200/110 mmHg, recent stroke or transient ischemic attack).
- • Patients on anticoagulant or antithrombotic treatment, ongoing or discontinued within the last month.
- • Patients treated for pulmonary embolism who remain dyspneic after anticoagulant treatment and requiring a work-up for pulmonary hypertension.
- • Last surgery dating back to less than 3 months.
- • Known chronic morbidities: diabetes mellitus, chronic inflammatory or infectious disease, heart failure, renal insufficiency, hepatic insufficiency or arterial thrombosis dating back to less than 3 months.
- • For women: treatment containing synthetic or natural estrogen, in progress or discontinued for less than a month
- • Pregnancy within the last year.
- • Difficult venous access.
- • Regular practice of an intensive sporting/physical activity, such as running, tennis, cycling etc. of more than 3 hours per week.
Trial Officials
Antonia PEREZ MARTIN, Prof.
Principal Investigator
Nîmes University Hospital
Stéphane FAURE
Principal Investigator
Nîmes University Hospital
About Centre Hospitalier Universitaire De Nīmes
The Centre Hospitalier Universitaire de Nîmes (CHU Nîmes) is a leading academic medical center located in Nîmes, France, dedicated to advancing healthcare through innovative clinical research and patient care. As a prominent sponsor of clinical trials, CHU Nîmes collaborates with a multidisciplinary team of healthcare professionals and researchers to conduct rigorous studies aimed at improving treatment outcomes and enhancing medical knowledge across various specialties. With a strong commitment to ethical standards and patient safety, CHU Nîmes fosters a research environment that encourages scientific excellence and contributes to the development of new therapies and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0